THE WOODLANDS, Texas--(BUSINESS WIRE)--Repros Therapeutics (NasdaqCM: RPRX) today announced the results of the proxy vote provided by the shareholders at its 2010 Annual Meeting as pertaining to the proposals set forth in the Company’s proxy statement. All proposals submitted to the shareholders were approved by the necessary vote. As a result, all current Board members will be retained and PricewaterhouseCoopers LLP will be retained as the Company’s registered independent public accounting firm.
